Correction to: SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017)

Correction to: Clin Transl Oncol 10.1007/s12094-017-1783-2

The original article shows two mistakes, which are listed here:

1. In paragraph 6 of the section “Second-line therapy: cabazitaxel and second-line hormone therapy” there was a mistake in line 6; instead of 0.65, it should have been written 0.74:

Overall survival was longer in the abiraterone group (14.8 months vs. 10.9 months; hazard ratio, 0.74; p < 0.001).

• 2.In the original version of this article two algorithms were referenced in section “Methodology”, but were not included in the article. The missing algorithms are listed here:

Algorithm 1: Castration resistant disease

Algorithm 2: Hormonosensitive disease